127 studies found for:    IGF1R
Show Display Options
Rank Status Study
1 Not yet recruiting Predictive Biomarkers for IGF1R Targeted Therapy in Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Biological: IGF1R antibody MK0646;   Other: Saline solution
2 Completed Retrospective Study Evaluating IGF1R And p95HER2 as Prognostic Factors in Non Small Cell Lung Cancer (NSCLC)
Condition: Non Small Cell Lung Cancer
Intervention: Genetic: Protein expression by immunohistochemistry and immunofluorescence
3 Not yet recruiting Predictive Biomarkers for IGF1R Targeted Therapy in Ovarian Cancer: a Retrospective Study
Condition: Ovarian Cancer
Intervention: Other: Immunohistochemistry staining method
4 Completed Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors
Condition: Solid Tumors
Intervention: Drug: BIIB022
5 Recruiting Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma
Conditions: Malignant Glioma;   Neoplasms
Interventions: Drug: IGF-1R/AS ODN; Surgery with tissue harvest and implantation 10 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 24 hours.;   Drug: IGF-1R/AS ODN; Surgery with tissue harvest and implantation 10 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 48 hours.;   Drug: IGF-1R/AS ODN; Surgery with tissue harvest and implantation of 20 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 24 hours.;   Drug: IGF-1R/AS ODN; Surgery with tissue harvest and implantation of 20 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 48 hours.
6 Completed Study of AVE1642 Anti-IGF1R Monoclonal Antibody in Patients With Advanced Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: AVE1642;   Drug: Velcade
7 Suspended Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors
Condition: Advanced Refractory Solid Tumors
Intervention: Drug: PL225B
8 Terminated Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer
Condition: Breast Neoplasms
Interventions: Drug: AVE1642;   Drug: Fulvestrant
9 Terminated
Has Results
IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery
Conditions: Recurrent Adrenocortical Carcinoma;   Stage III Adrenocortical Carcinoma;   Stage IV Adrenocortical Carcinoma
Interventions: Biological: IMC-A12;   Drug: mitotane
10 Withdrawn Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: IGF-1R inhibitor OSI-906;   Drug: erlotinib hydrochloride;   Drug: goserelin;   Drug: letrozole
11 Completed A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: BIIB022 With Paclitaxel and Carboplatin
12 Completed A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors
Conditions: Askin's Tumors;   Desmoplastic Small Round Cell Tumors;   Estraosseous Ewing's Tumor;   Ewing's Family Tumor;   Ewing's Sarcoma;   Primitive Neuroectodermal Tumors (PNETs);   Sarcoma
Intervention: Drug: AMG 479
13 Active, not recruiting Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
Conditions: Adult Hepatocellular Carcinoma;   Advanced Adult Hepatocellular Carcinoma;   Localized Non-Resectable Adult Liver Carcinoma;   Recurrent Adult Liver Carcinoma
Interventions: Biological: Cixutumumab;   Other: Laboratory Biomarker Analysis;   Drug: Sorafenib Tosylate
14 Terminated
Has Results
Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology
Conditions: Carcinoma, Squamous Cell;   Carcinoma, Adenosquamous;   Carcinoma, Large Cell;   Carcinoma, Non-Small-Cell Lung
Interventions: Drug: CP-751,871 (Figitumumab);   Drug: Carboplatin;   Drug: Paclitaxel
15 Completed A Study to Evaluate the Biological Activity of R1507 in Women With Operable Breast Cancer
Condition: Breast Cancer
Intervention: Drug: RG1507
16 Completed Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)
Condition: Hepatocellular Carcinoma
Interventions: Drug: BIIB022;   Drug: Sorafenib
17 Recruiting Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R
Conditions: Breast Cancer;   Brain Cancer;   Gastrointestinal Cancers;   Genitourinary Cancers;   Gynecologic Cancers;   Head and Neck Cancers;   Melanoma;   Thoracic Cancers
Intervention: Drug: IGF-Methotrexate
18 Completed A Study of the IGF-1R Inhibitor AXL1717 in Combination With Gemcitabine HCL and Carboplatin to Treat Non-small-cell Lung Cancer (NSCLC)
Condition: Non Small Cell Lung Cancer
Intervention: Drug: AXL1717
19 Active, not recruiting Studying Tissue Samples From Women With Breast Cancer Who Were Treated on Clinical Trial NCCTG-N9831
Condition: Breast Cancer
Intervention: Other: diagnostic laboratory biomarker analysis
20 Active, not recruiting
Has Results
Cisplatin and Etoposide With or Without Vismodegib or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Extensive Stage Small Cell Lung Cancer;   Recurrent Small Cell Lung Cancer
Interventions: Biological: cixutumumab;   Drug: vismodegib;   Drug: cisplatin;   Drug: etoposide

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years